Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing

A method for treating Hutchinson-Gilford Progeria Syndrome or vascular ageing diseases comprising administering an effective amount of a metalloprotease inhibitor comprising a zinc endopeptidase, wherein said inhibitor is selected from the following compounds:

• pyrimidine-4,6-dicarboxylic acid, bis-(4-fluoro-3-methyl-benzylamide);
• pyrimidine-4,6-dicarboxylic acid, bis-(3-methyl-benzylamide);
• pyrimidine-4,6-dicarboxylic acid, bis-(benzylamide);
• pyrimidine-4,6-dicarboxylic acid bis-[(Pyridin-3-YL-Methyl)-Amide;
• (2R,3S)-N4-Hydroxy-2-isobutyl-N1-[(2S)-1-(methylamino)-1-oxo-3-phenyl-2-propanyl]-3-[(2-thienylsulfanyl)methyl]succinamide;
• N-[2,2-dimethyl-1-(methylcarbamoyl)propyl]-2-[hydroxy-(hydroxycarbamoyl)methyl]-4-methyl-pentanamide;
• N-hydroxy-4-((4-((4-hydroxy-2-butynyl)oxy)phenyl)sulfonyl)-2,2-dimethyl-3-thiomorpholinecarboxamide;
• MMP-13 siRNA, and mixtures thereof,
• to a patient in need thereof.